Lijuan Li

Dr. Lijuan Li

Department of Cancer Prevention Center, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
WSWang Shuang
Wang Shuang
LLLijuan Li
Lijuan Li
MYMengmeng Yang
Mengmeng Yang
XWXiaoyan Wang
Xiaoyan Wang
HZHuan Zhang
Huan Zhang
JLJuntian Liu
Juntian Liu
The diagnostic value of microRNAs (miRNAs) for breast cancer (BC) is largely unknown. Here, our research aim was to explore new circulating miRNAs for BC diagnosis. First, we identified 14 common differentially expressed miRNAs in tissues by TCGA_BRCA and GSE97811 datasets and preliminarily validated them in serum by the GSE73002 dataset. Furthermore, we examined three plasma miRNAs in BC patients (n = 108) and healthy subjects (n = 103) by RT–PCR, namely, hsa-miR-100-5p, hsa-miR-191-5p and hsa-miR-342-3p. The levels of these three miRNAs in BC patients were higher than those in healthy controls (p < 0.05). The ROC curve analysis revealed that these three miRNAs had high diagnostic efficacy for BC and early-stage BC. The combination of hsa-miR-100-5p and hsa-miR-191-5p was the optimal combination for the diagnosis of BC and early-stage BC. Additionally, hsa-miR-100-5p was correlated with stage I–II, T1 stage, N0 stage and Luminal A subtype (p < 0.05). Hsa-miR-191-5p and hsa-miR-342-3p were irrelevant to TNM stage, T stage, N stage and molecular subtypes. Meanwhile, the biological function analysis indicated that these three miRNAs are mainly involved in the calcium signaling pathway, MAPK signaling pathway and microRNAs in cancer. In conclusion, these three miRNAs demonstrate a positive effect on detection and discovery in BC.

11 October 2022 in Research Square
Verified
Preprint
Open access
PDF file
YZYu Zeng
Yu Zeng
WMWEIKE MA
WEIKE MA
LLLijuan Li
Lijuan Li
GZGaojian Zhuang
Gaojian Zhuang
GLGuoqing Luo
Guoqing Luo
XZXiangqian Zheng
Xiangqian Zheng
Papillary thyroid cancer (PTC) is one of the most common malignant tumors in female, and estrogen can affect its progression. However, the targets and mechanisms of estrogen action in PTC remain unclear. Therefore, this study focuses on the relationship between estrogen-related genes (ERGs) expression and prognosis in PTC, particularly neuropeptide U (NMU), and its important role in the development of PTC. We first downloaded expression data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases for PTC and normal tissue and identified differentially expressed genes (DEGs), which were predominantly enriched for ERGs. Then, we identified ERGs that contributed most to PTC prognosis based on univariate Cox regression and Lasso Cox analysis. We filtered out Transducer of ERBB2 1 (TOB1), trefoil factor 1 (TFF1), phospholipase A and acyltransferase 3 (PLAAT3), NMU, kinesin family member 20A (KIF20A), DNA topoisomerase II alpha (TOP2A), tetraspanin 13 (TSPAN13), and carboxypeptidase E (CPE). In addition, we explored the effect of NMU on the proliferation of PTC cells by in vitro experiments, confirmed high NMU expression in PTC and showed that the proliferative capacity of PTC cells was significantly reduced with NMU knockdown. Moreover, the phosphorylation levels of the Kirsten rat sarcoma virus (KRAS) signaling pathway were significantly lower with NMU knockdown. These results suggest that ERGs, especially NMU, may be novel prognostic indicators in PTC.